Cancer Research and Treatment

Cancer Research and Treatment Search

> Browse Articles > Search

Breast cancer

Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study

Kuikui Jiang, Ruoxi Hong, Wen Xia, Qianyi Lu, Liang Li, Jianhao Huang, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Fei Xu, Shusen Wang

Cancer Res Treat. 2024;56(2):513-521. Published online October 12, 2023 DOI: https://doi.org/10.4143/crt.2023.786

Lung and Thoracic cancer

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Miso Kim, Soyeon Kim, Jeemin Yim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Dae Seog Heo

Cancer Res Treat. 2023;55(4):1134-1143. Published online May 23, 2023 DOI: https://doi.org/10.4143/crt.2023.311

Hematologic malignancy

Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia

Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu

Cancer Res Treat. 2023;55(3):1023-1030. Published online February 6, 2023 DOI: https://doi.org/10.4143/crt.2022.1618

Lung and Thoracic cancer

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study

Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng

Cancer Res Treat. 2023;55(3):841-850. Published online February 13, 2023 DOI: https://doi.org/10.4143/crt.2022.1438

Crossref 3

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma

Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang

Cancer Res Treat. 2022;54(2):434-444. Published online August 2, 2021 DOI: https://doi.org/10.4143/crt.2021.671

Web of Science 7 Crossref 9

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn

Cancer Res Treat. 2020;52(4):1288-1290. Published online June 22, 2020 DOI: https://doi.org/10.4143/crt.2020.278

Web of Science 17 Crossref 7

Breast cancer

Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis

Ying Lin, Mingxi Lin, Jian Zhang, Biyun Wang, Zhonghua Tao, Yiqun Du, Sheng Zhang, Jun Cao, Leiping Wang, Xichun Hu

Cancer Res Treat. 2020;52(4):1059-1066. Published online April 24, 2020 DOI: https://doi.org/10.4143/crt.2019.633

Web of Science 30 Crossref 16

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

Tian-Hao Weng, Min-Ya Yao, Xiang-Ming Xu, Chen-Yu Hu, Shu-Hao Yao, Yi-Zhi Liu, Zhi-Gang Wu, Tao-Ming Tang, Pei-Fen Fu, Ming-Hai Wang, Hang-Ping Yao

Cancer Res Treat. 2020;52(3):973-986. Published online April 22, 2020 DOI: https://doi.org/10.4143/crt.2019.726

Web of Science 14 Crossref 14

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee

Cancer Res Treat. 2020;52(1):284-291. Published online July 23, 2019 DOI: https://doi.org/10.4143/crt.2019.200

Web of Science 5 Crossref 4

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo

Cancer Res Treat. 2019;51(3):951-962. Published online October 10, 2018 DOI: https://doi.org/10.4143/crt.2018.052

Web of Science 42 Crossref 41

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

Cancer Res Treat. 2019;51(2):623-631. Published online July 23, 2018 DOI: https://doi.org/10.4143/crt.2018.151

Web of Science 41 Crossref 34

Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma

In Kyoung Hwang, Seung Sook Paik, Seung Hyeun Lee

Cancer Res Treat. 2019;51(1):158-168. Published online April 2, 2018 DOI: https://doi.org/10.4143/crt.2018.084

Web of Science 15 Crossref 13

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors

Jiyoul Yang, Ok-Jun Lee, Seung-Myoung Son, Chang Gok Woo, Yusook Jeong, Yaewon Yang, Jihyun Kwon, Ki Hyeong Lee, Hye Sook Han

Cancer Res Treat. 2018;50(3):908-916. Published online September 19, 2017 DOI: https://doi.org/10.4143/crt.2017.378

Web of Science 31 Crossref 25

Incorporating Neutrophil-to-lymphocyte Ratio and Platelet-to-lymphocyte Ratio in Place of Neutrophil Count and Platelet Count Improves Prognostic Accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model

Pawel Chrom, Rafal Stec, Lubomir Bodnar, Cezary Szczylik

Cancer Res Treat. 2018;50(1):103-110. Published online March 3, 2017 DOI: https://doi.org/10.4143/crt.2017.033

Web of Science 26 Crossref 28

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer

Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han

Cancer Res Treat. 2017;49(4):1001-1011. Published online January 13, 2017 DOI: https://doi.org/10.4143/crt.2016.546

Web of Science 38 Crossref 33

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status

Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee

Cancer Res Treat. 2017;49(4):981-989. Published online January 6, 2017 DOI: https://doi.org/10.4143/crt.2016.522

Web of Science 12 Crossref 12

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis

Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang

Cancer Res Treat. 2016;48(3):1110-1119. Published online January 6, 2016 DOI: https://doi.org/10.4143/crt.2015.289

Web of Science 6 Crossref 7

The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo

Keun-Yong Eom, Bong Jun Cho, Eun Jung Choi, Jin-Ho Kim, Eui Kyu Chie, Hong-Gyun Wu, Il Han Kim, Sun Ha Paek, Jae-Sung Kim, In Ah Kim

Cancer Res Treat. 2016;48(2):687-697. Published online June 4, 2015 DOI: https://doi.org/10.4143/crt.2014.320

Web of Science 25 Crossref 22

Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea

Jaemin Jo, Jung Ho Kim, Ji Young Kim, Changlim Hyun, Jiyoung Rhee, Jungmi Kwon, Sanghoon Han, Wookun Kim

Cancer Res Treat. 2016;48(1):393-397. Published online February 17, 2015 DOI: https://doi.org/10.4143/crt.2014.209

A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib

Meral Gunaldi, Ismail Oguz Kara, Berna Bozkurt Duman, Cigdem Usul Afsar, Melek Ergin, Arbil Avci

Cancer Res Treat. 2014;46(4):411-414. Published online July 18, 2014 DOI: https://doi.org/10.4143/crt.2013.093

Web of Science 3 Crossref 2

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo

Cancer Res Treat. 2014;46(4):323-330. Published online July 14, 2014 DOI: https://doi.org/10.4143/crt.2013.120

Web of Science 22 Crossref 18

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim

Cancer Res Treat. 2013;45(2):79-85. Published online June 30, 2013 DOI: https://doi.org/10.4143/crt.2013.45.2.79

Crossref 14

Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer

D. Nathan Kim, Taek-Keun Nam, Kevin S. Choe, Hak Choy

Cancer Res Treat. 2012;44(2):74-84. Published online June 30, 2012 DOI: https://doi.org/10.4143/crt.2012.44.2.74

Crossref 5

Analysis of Response and Progression Patterns of Tyrosine Kinase Inhibitors in Recurrent or Metastatic Adenoid Cystic Carcinoma: A Post Hoc Analysis of Two KCSG Phase II Trials

Youjin Kim, Bhumsuk Keam, Eun Joo Kang, Jin-Soo Kim, Hye Ryun Kim, Keun-Wook Lee, Jung Hye Kwon, Kyoung Eun Lee, Yaewon Yang, Yoon Hee Choi, Min Kyoung Kim, Jun Ho Ji, Tak Yun, Moon Young Choi, Ki Hyeong Lee, Sung-Bae Kim, Myung-Ju Ahn

Received January 2, 2024 Accepted April 14, 2024 Published online April 15, 2024
DOI: https://doi.org/10.4143/crt.2024.008
[Accepted]